BofA/Merrill Lynch Starts ProNAi Therapeutics (DNAI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts DNAI Hot Sheet
Price: $1.56 --0%
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
BofA/Merrill Lynch initiated coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Buy rating and a price target of $35.00.
For an analyst ratings summary and ratings history on ProNAi Therapeutics click here. For more ratings news on ProNAi Therapeutics click here.
Shares of ProNAi Therapeutics closed at $28.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Double Downgrades NVR Inc. (NVR) to Underperform
- Cantor Fitzgerald Starts Quantum Corp. (QMCO) at Overweight
- Cantor Fitzgerald Starts Immunic Inc. (IMUX) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
